Public Company Healthcare

Otsuka Pharmaceutical

Chiyoda, Tokyo, Japan

Global healthcare and pharmaceutical company focused on discovery, development, manufacturing and commercialization of innovative medicines (and related health products).

Focus Areas
Pharmaceuticals, Biotechnology, Therapeutics / drug development
Website
otsuka.co.jp/en

Tracked deals

3

3 tracked deals across 2023-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

3 buyout

Otsuka Pharmaceutical Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Otsuka Pharmaceutical. 1 2023 1 2024 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Otsuka Pharmaceutical Acquires Transcend Therapeutics
    March 27, 2026
    Buyer
    Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc., Otsuka America Pharmaceutical, Inc.
    Target
    Transcend Therapeutics, Inc.
    Seller
    Transcend shareholders
    Industry
    Biotechnology
    Location
    New York, United States
    Type
    Buyout

    Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.

  • Otsuka Pharmaceutical Acquires Jnana Therapeutics
    August 1, 2024
    Buyer
    Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc.
    Target
    Jnana Therapeutics Inc.
    Seller
    Shareholders of Jnana Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

  • Otsuka Pharmaceutical Acquires Mindset Pharma
    August 31, 2023
    Buyer
    Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc.
    Target
    Mindset Pharma Inc.
    Industry
    Biotechnology
    Location
    Ontario, Canada
    Type
    Buyout

    Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Otsuka Pharmaceutical. Acquisitions in Massachusetts 1 tracked deal by Otsuka Pharmaceutical. Acquisitions in New York 1 tracked deal by Otsuka Pharmaceutical.

Selling a company? Get in front of buyers like Otsuka Pharmaceutical

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →